XML 40 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of (Loss) Income - USD ($)
shares in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues [Abstract]      
Product sales $ 0 $ 22,334,000 $ 59,215,000
Operating expenses:      
Cost of products 0 5,742,000 12,125,000
Research and development expenses 17,104,000 20,442,000 32,917,000
Selling, general and administrative expenses 68,495,000 32,405,000 30,183,000
Intangible asset amortization 0 406,000 816,000
Changes in fair value of contingent consideration 0 3,327,000 845,000
Gain on sale of Hospital Products 0 (45,760,000) 0
Restructuring (income) costs (53,000) (43,000) 6,441,000
Total operating expenses 85,546,000 16,519,000 83,327,000
Operating (loss) income (85,546,000) 5,815,000 (24,112,000)
Investment and other income (expense), net 2,126,000 (832,000) 1,069,000
Interest expense (9,942,000) (12,994,000) (12,483,000)
Gain from release of certain liabilities 217,000 3,364,000 0
Loss on deconsolidation of subsidiary 0 0 (2,678,000)
Other expense - changes in fair value of contingent consideration payable 0 (435,000) (378,000)
Loss before income taxes (93,145,000) (5,082,000) (38,582,000)
Income tax benefit (15,816,000) (12,110,000) (5,356,000)
Net (loss) income $ (77,329,000) $ 7,028,000 $ (33,226,000)
Earnings (loss) per share      
Net income (loss) per share - basic (in usd per share) $ (1.32) $ 0.13 $ (0.89)
Net income (loss) per share - diluted (in usd per share) $ (1.32) $ 0.13 $ (0.89)
Weighted average number of shares outstanding      
Weighted average number of shares outstanding - basic (in shares) 58,535 52,996 37,403
Weighted average number of shares outstanding - diluted (in shares) 58,535 54,941 37,403